|
WO2021062406A1
|
|
Cytokine prodrugs and dual-prodrugs
|
|
WO2021035188A1
|
|
Novel il-21 prodrugs and methods of use thereof
|
|
WO2021030483A1
|
|
Il-2 fusion proteins that preferentially bind il-2ralpha
|
|
US2020392235A1
|
|
Novel il-15 prodrugs and methods of use thereof
|
|
WO2020150282A1
|
|
Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis
|
|
WO2020023702A1
|
|
Novel il-21 prodrugs and methods of use thereof
|
|
US2020040101A1
|
|
Novel antibodies and methods for making and using the same
|
|
WO2019209716A2
|
|
Pharmaceutical formulations for novel feline erythropoietin receptor agonists
|
|
EP3775267A2
|
|
Novel angiopoietin 2, vegf dual antagonists
|
|
US2020102381A1
|
|
Novel angiopoietin 2, vegf dual antagonists
|
|
WO2019173832A2
|
|
Cytokine prodrugs
|
|
WO2019152827A1
|
|
Novel antibody-drug conjugates (adc), methods of making, and methods of use thereof
|
|
US2019106494A1
|
|
PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
|
|
WO2018026742A1
|
|
Novel antibody-albumin-drug conjugates (aadc) and methods for using them
|
|
WO2018009921A1
|
|
Fusion protein comprising leptin and methods for producing and using the same
|
|
CN109414500A
|
|
Treatment and diagnosis PD-L1 monoclonal antibody specific
|
|
EP3454903A1
|
|
Novel angiopoietin 2, vegf dual antagonists
|
|
US2016137712A1
|
|
Fusion Proteins With Dual Receptor Agonist Activities
|
|
EP3194429A2
|
|
Novel feline erythropoietin receptor agonists
|
